Drug Landscape ›
Atorvastatin Calcium Tablets ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 218
Most-reported reactions
Myalgia — 33 reports (15.14%) Muscle Spasms — 29 reports (13.3%) Dysgeusia — 24 reports (11.01%) Nausea — 22 reports (10.09%) Pain In Extremity — 22 reports (10.09%) Dizziness — 20 reports (9.17%) Drug Ineffective — 18 reports (8.26%) Arthralgia — 17 reports (7.8%) Rash — 17 reports (7.8%) Diarrhoea — 16 reports (7.34%)
Source database →
Atorvastatin Calcium Tablets in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Atorvastatin Calcium Tablets approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Atorvastatin Calcium Tablets in United States?
NYU Langone Health is the originator. The local marketing authorisation holder may differ — check the official source linked above.